Aqemia
About Aqemia
Aqemia
Aqemia is a next-generation pharmatech company founded in 2019 as a deeptech spinoff from École Normale Supérieure that revolutionizes drug discovery by combining quantum-inspired physics algorithms with generative AI, enabling molecule exploration 10,000 times faster than conventional methods without requiring experimental training data. In 2024, Aqemia raised €60 million in Series A funding led by Cathay Innovation, bringing total funding to over €100 million, to prepare for clinical trials and fuel international expansion with a new London office opening in January 2025. The company currently has three cancer-targeting drug candidates undergoing preclinical animal testing, having progressed to this stage in under two years with expectations to move into clinical trials by 2025. Aqemia’s quantum-inspired algorithms simulate molecular behavior at unprecedented accuracy and speed, training AI models on physical laws governing molecular structures. Major partnerships include a $140 million collaboration with Sanofi and agreements with Servier and Johnson & Johnson to accelerate oncology drug development through physics-based molecular design.
Company Information
- Founded: 2019
- Country: France
- Website: https://aqemia.com
- Categories: applications
Investment Information
- Status: private
- Total Raised: $200M
- Last Valuation: $500M
Recent Funding Rounds
- 2024-04-16: strategic - $140M - Strategic partnership with Sanofi for oncology drug development
- 2022-10-25: series-b - $60M - Series B funding round
Related Companies
Explore other quantum computing companies in similar categories or regions.
Company Information
Investment Information
Status
Private
Total Raised
$200M
2 funding rounds tracked. View detailed investment history →
⚠️ Important Disclaimer
Information for Educational Purposes Only: All information about Aqemia is provided for informational and educational purposes only. This is not investment, financial, or professional advice.
No Warranties: While we strive for accuracy, Quantum Zeitgeist makes no warranties regarding the accuracy, completeness, or timeliness of company information. The quantum technology industry evolves rapidly, and information may become outdated.
No Endorsement: Inclusion in Quantum Navigator does not constitute an endorsement, recommendation, or verification of Aqemia's claims, technology, or business viability.
Do Your Own Research: Always conduct independent due diligence and consult qualified professionals (financial advisors, lawyers, etc.) before making investment, business, or career decisions.
For more information, see our Terms of Service and Privacy Policy.